HANGZHOU, China. – 6 April 2021 – Ranok Therapeutics Co. Ltd., a biopharmaceutical company focused on developing therapeutics for cancers and other serious diseases, today announced that it will present a poster this week at the 112th American Association for Cancer Research (AACR) Annual Meeting, which will be held virtually from 10-15 April 2021 and 17-21 May 2021. The poster will describe the identification of tumor-targeted, selective protein degraders of the cancer target BRD4 using Ranok’s CHAMPTM technology platform.
Details for the poster presentation are as follows:
Title: Chaperone-mediated protein degradation (CHAMPTM): A novel technology for tumor-targeted protein degradation
Date and Time: 10 April 2021 at 8:30AM EDT
Presenter: Kevin P. Foley, Ph.D., Ranok’s Co-founder and Chief Scientific Officer
Session: Small Molecule Therapeutic Agents (PO.ET06.08)
Poster abstract: Available online at AACR21 Poster 971.
The poster will be available online to registered conference attendees and will also be available on Ranok’s website beginning on Saturday 10 April 2021.
About Ranok Therapeutics
Ranok is a privately held, emerging biopharmaceutical company that is pioneering its proprietary CHAMPTM platform technology, an innovative approach to targeted protein degradation for the discovery and development of novel therapeutics. Ranok was founded by a leadership team composed of industry veterans from both Chinese and American biotech and pharmaceutical companies and is based in two of the world’s leading centers of innovation and medical research: Hangzhou China and Boston Massachusetts USA. By bringing together cutting edge medical research from both China and the United States, Ranok's goal is to create transformative medicines to benefit patients suffering from cancer and other serious diseases. For more information, please visit the company website at www.ranoktherapeutics.com or follow us at LinkedIn and on Twitter @RanokTx.
About Ranok's CHAMPTM platform
Chaperone-mediated Protein Degradation/Degrader (CHAMPTM) technology is based on our founders' extensive backgrounds in protein homeostasis research. This technology takes advantage of different underlying biological processes from other targeted protein degradation approaches such as PROTAC, and has a number of unique advantages, including improved safety due to the selective targeting of tumors. Our proprietary R&D engine combines deep biological insight and chemistry expertise to iteratively discover and test new leads, rapidly identifying and advancing optimal development candidates for a variety of important disease targets.
Media & Investor Contact:
Mr. Lei Zhang
Ranok Therapeutics Co. Ltd.